Molecular Targets of Anti-Glutamine Therapy with Acivicin in Cancer Cells
Authors:
- G. WeberGWG. Weber
- M. S. LuiMLM. S. Lui
- J. SeboldtJSJ. Seboldt
- 1 January 1984
- book chapter
- Published by Springer Nature
- p. 278-291
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Salvage capacity of hepatoma 3924A and action of dipyridamoleAdvances in Enzyme Regulation, 1983
- Multi-enzyme-targeted chemotherapy by acivicin and actinomycinAdvances in Enzyme Regulation, 1982
- Biochemical pharmacology of acivicin in rat hepatoma cellsBiochemical Pharmacology, 1982
- In vivo inactivation by acivicin of carbamoylphosphate synthetase II in rat hepatomaBiochemical Pharmacology, 1982
- Rapid in vivo inactivation by acivicin of CTP synthetase, carbamoyl-phosphate synthetase II, and amidophosphoribosyltransferase in hepatomaLife Sciences, 1982
- Role of ribonucleotide reductase in expression of the neoplastic programLife Sciences, 1981
- Transcriptionally active RNA polymerases from Morris hepatomas and rat liver. Elucidation of the mechanism for the preferential increase in the tumour RNA polymerase IBiochemical Journal, 1980
- Mechanism of inactivation of glutamine amidotransferases by the antitumor drug L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).Journal of Biological Chemistry, 1980
- Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (αS, 5S) -α-amino-3-chloro-4, 5-dihydro-5-isoxazoleacetic acid (at-125)Advances in Enzyme Regulation, 1979
- Enzymology of Cancer CellsNew England Journal of Medicine, 1977